Akebia Therapeutics Inc
SWB:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
SWB:AX9
|
US |
|
E
|
Eurofins Scientific SE
DUS:ESF0
|
LU |
|
W
|
Wheaton Precious Metals Corp
DUS:SII
|
CA |
|
Dynavax Technologies Corp
NASDAQ:DVAX
|
US |
|
K
|
Kongsberg Automotive ASA
F:K3A
|
NO |
|
W
|
Worthington Industries Inc
F:WTH
|
US |
|
M
|
Markel Corp
LSE:0JYM
|
US |
|
D
|
Darma Henwa Tbk PT
SWB:0DH
|
ID |
|
Cass Information Systems Inc
NASDAQ:CASS
|
US |
|
H&R Real Estate Investment Trust
F:HR3A
|
CA |
|
Francotyp Postalia Holding AG
F:FPH
|
DE |
|
T
|
Tutor Perini Corp
F:PE2
|
US |
|
Pinnacle Financial Partners Inc
NASDAQ:PNFP
|
US |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.6 EUR with a low forecast of 2.54 EUR and a high forecast of 5.29 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.6
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.6 EUR with a low forecast of 2.54 EUR and a high forecast of 5.29 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-1%
The compound annual growth rate for Gross Profit over the next 3 years is -1%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
34%
The compound annual growth rate for Operating Income over the next 8 years is 34%.
